PARNATE

This brand name is authorized in Australia, Brazil, Canada, Estonia, Ireland, New Zealand, United States

Active ingredients

The drug PARNATE contains one active pharmaceutical ingredient (API):

1 Tranylcypromine UNII 7ZAT6ES870 - TRANYLCYPROMINE SULFATE

Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor for the treatment of symptoms of depressive illness especially where phobic symptoms are present or where treatment with other types of anti-depressants has failed.

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
PARNATE Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N06AF04	Tranylcypromine	N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AF Monoamine oxidase inhibitors, non-selective
Discover more medicines within N06AF04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 2444P
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 510612110048403
Country: CA	Health Products and Food Branch	Identifier(s): 01919598
Country: EE	Ravimiamet	Identifier(s): 1799972, 1799994
Country: IE	Health Products Regulatory Authority	Identifier(s): 39722
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 3412
Country: US	FDA, National Drug Code	Identifier(s): 59212-447